US2012237768A1PendingUtilityA1
Method for producing pulverized organic compound particle
Est. expiryApr 6, 2027(~0.7 yrs left)· nominal 20-yr term from priority
A61P 37/06A61P 3/06A61P 5/38A61P 35/00A61P 3/10A61P 9/06A61P 5/00A61P 9/10A61P 7/04A61P 9/04A61P 37/08A61P 9/12A61P 7/00A61P 9/00A61P 43/00A61P 31/12A61P 25/08A61P 25/24A61P 31/04A61P 25/02A61P 25/20A61P 25/16A61P 3/02A61P 27/02A61P 29/00A61P 25/18A61P 27/16A61P 31/10A61P 25/22A61K 31/404A61K 31/015A61K 31/56A61K 9/14A61K 9/0019A61K 31/4174A61P 1/02A61K 31/41A61P 1/14A61P 11/00A61P 11/06A61P 11/14Y10T428/2982A61K 31/573A61P 19/00A61P 19/06A61P 1/10A61P 1/04A61P 19/10A61P 1/12A61K 31/4422A61K 31/216A61P 11/10A61K 31/57A61P 11/08A61P 21/02A61P 13/02A61K 31/4704A61K 9/0073A61K 31/192A61K 9/16A61K 47/10
42
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed is a method for producing pulverized particles of a crystalline organic compound which is poorly water-soluble. Also disclosed is a pulverized organic compound particle produced by such a method. Specifically disclosed is a method for producing a poor water solubility organic compound particle for medical use, which is characterized in that a poor water solubility organic compound for medical use is mixed with a physiologically acceptable salt and a physiologically acceptable polyol, and subjected to wet milling. Also specifically disclosed is a poor water solubility organic compound particle for medical use, which is produced by such a production method.
Claims
exact text as granted — not AI-modified1 - 12 . (canceled)
13 . Poorly water-soluble organic compound fine particles for medical use, which has a melting point or a decomposition point in the range of 80 to 350 degrees C., is crystalline and has an average diameter of 600 nm or less.
14 . Poorly water-soluble organic compound fine particles for medical use according to claim 13 ,
wherein content of fine particles of 0.2 micron or less in diameter in pulverized organic compound particles is 70% or more.
15 . Poorly water-soluble organic compound fine particles for medical use according to claim 13 ,
wherein 90% diameter of the poorly water-soluble organic compound fine particles for medical use is 600 nm or less.
16 . Poorly water-soluble organic compound fine particles for medical use according to claim 13 ,
wherein the poorly water-soluble organic compound includes no surface active agent.
17 . Poorly water-soluble organic compound fine particles for medical use according to claim 13 ,
wherein the poorly water-soluble organic compound is one or more organic compounds selected from the group consisting of nifedipine, nicardipine, nimodipine, dipyridamole, diisopyramide, prazosin hydrochloride, prednisolone, cortisone acetate, dexamethasone, betamethasone, beclometasone dipropionate, fluticasone propionate, budesonide, fluocinolone acetonide, indomethacin, naproxen, ketoprofen, 7-[(3,5-dimethoxy-4-hydroxycinnamoyl)amino]-3-octyloxy-4-hydroxy-1-methyl-2(1H)-quinolinone, phenyloin, phenacemide, ethotoin, primidone, diazepam, nitrazepam, clonazepam, digitoxin, spironolactone, triamterene, chlorthalidone, polythiazide, benzthiazide, griseofulvin, nalidixic acid, chloramphenicol, chlorzoxazone, phenprobamate, mequitazine, bisbentiamin, mitomycin C, bicalutamide, paclitaxel, ubenimex, dacarbazine, fluconazole, miconazole, rifampicin, triamcinolone acetonide, clemastine fumarate, pranlukast hydrate, zafirlukast, fenofibrate, dihydroxybenzophenone, dihydrocholesterol, beta-carotene, propyl gallate, cinnamic acid, saccharin, folic acid and maltol.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.